DB:DSH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sensyne Health plc, a healthcare technology company, engages in the development and commercialization of clinically validated software in the United Kingdom.


Snowflake Analysis

Adequate balance sheet and fair value.


Similar Companies

Share Price & News

How has Sensyne Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DSH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.6%

DSH

3.6%

DE Healthcare Services

-3.6%

DE Market


1 Year Return

-79.9%

DSH

9.4%

DE Healthcare Services

3.7%

DE Market

Return vs Industry: DSH underperformed the German Healthcare Services industry which returned 9.4% over the past year.

Return vs Market: DSH underperformed the German Market which returned 3.8% over the past year.


Shareholder returns

DSHIndustryMarket
7 Day-0.6%3.6%-3.6%
30 Day-10.0%2.8%-2.0%
90 Day-31.6%10.9%13.3%
1 Year-79.9%-79.9%10.1%9.4%6.0%3.7%
3 Yearn/a53.2%49.5%1.1%-6.9%
5 Yearn/a155.8%145.2%7.8%-6.8%

Price Volatility Vs. Market

How volatile is Sensyne Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sensyne Health undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DSH (€0.34) is trading below our estimate of fair value (€4.48)

Significantly Below Fair Value: DSH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DSH is unprofitable, so we can't compare its PE Ratio to the XE Healthcare Services industry average.

PE vs Market: DSH is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DSH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DSH is good value based on its PB Ratio (0.7x) compared to the DE Healthcare Services industry average (3.6x).


Next Steps

Future Growth

How is Sensyne Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

47.3%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if DSH's forecast earnings growth is above the savings rate (0.2%).

Earnings vs Market: Insufficient data to determine if DSH's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DSH's revenue (47.3% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: DSH's revenue (47.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DSH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sensyne Health performed over the past 5 years?

-32.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: DSH is currently unprofitable.

Growing Profit Margin: DSH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if DSH's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare DSH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DSH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-10.8%).


Return on Equity

High ROE: DSH has a negative Return on Equity (-33.19%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sensyne Health's financial position?


Financial Position Analysis

Short Term Liabilities: DSH's short term assets (£41.9M) exceed its short term liabilities (£3.9M).

Long Term Liabilities: DSH's short term assets (£41.9M) exceed its long term liabilities (£1.8M).


Debt to Equity History and Analysis

Debt Level: DSH is debt free.

Reducing Debt: DSH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if DSH has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DSH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Sensyne Health current dividend yield, its reliability and sustainability?

1.03%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DSH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DSH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DSH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DSH's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Paul Drayson (59yo)

no data

Tenure

UK£1,280,000

Compensation

Lord Paul Drayson, PhD FIET FREng? co-founded Drayson Technologies Ltd. in 2014 and serves as its Chairman of the Board and Chief Executive Officer. He is a Member of the House of Lords. Lord Drayson serve ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD1.68M) is above average for companies of similar size in the German market ($USD469.66K).

Compensation vs Earnings: Insufficient data to compare Paul's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Drayson
CEO & Directorno dataUK£1.28m29.23% £13.6m
Lionel Tarassenko
Director of R&D1.83yrsUK£98.00kno data
Michael Norris
Interim Chief Financial Officer0.42yrno datano data
Alan Payne
Chief Information Officer0.58yrno datano data
Laura Hillier
General Counsel & Company Secretaryno datano datano data
James Chandler
Vice President of Communications0.25yrno datano data
Nick Scott-Ram
Chief of Strategic Developmentno datano datano data
Rabia Khan
Managing Director of Discovery Sciencesno datano datano data
Darren Lynch
Head of Designno datano datano data
Lucy Mackillop
Chief Medical Officer0.58yrno datano data
Roberto Liddi
Senior Vice President of Quality Regulatory & Information Governance0.58yrno datano data

0.6yrs

Average Tenure

Experienced Management: DSH's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Drayson
CEO & Directorno dataUK£1.28m29.23% £13.6m
Lionel Tarassenko
Director of R&D1.83yrsUK£98.00kno data
Vishal Gulati
Independent Non-Executive Director2yrsUK£24.00kno data
Bruce Keogh
Independent Non-Executive Chair of the Board0.67yrUK£24.00kno data
Lloyd Minor
Member of Scientific Advisory Boardno datano datano data
Michael Bewick
Member of Scientific Advisory Boardno datano datano data
Mary Hardy
Senior Independent Director0.67yrUK£28.00kno data
David Clifton
Member of Scientific Advisory Boardno datano datano data
Peter Watkinson
Member of Scientific Advisory Boardno datano datano data

1.8yrs

Average Tenure

59yo

Average Age

Experienced Board: DSH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sensyne Health plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sensyne Health plc
  • Ticker: DSH
  • Exchange: DB
  • Founded: 2018
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: UK£41.786m
  • Listing Market Cap: UK£46.408m
  • Shares outstanding: 128.57m
  • Website: https://www.sensynehealth.com

Number of Employees


Location

  • Sensyne Health plc
  • Schrodinger Building
  • Heatley Road
  • Oxford
  • Oxfordshire
  • OX4 4GE
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SENSAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPAug 2018
DSHDB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2018

Biography

Sensyne Health plc, a healthcare technology company, engages in the development and commercialization of clinically validated software in the United Kingdom. Its products include SEND, an early warning system for monitoring patient vital signs in hospital; GDm-Health, a prescribed digital therapeutic for the management of gestational diabetes at home; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. The company has strategic research alliance with Bayer's LifeHub UK to develop new treatments using clinical artificial intelligence. Sensyne Health plc was incorporated in 2018 and is headquartered in Oxford, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/02 21:03
End of Day Share Price2020/07/31 00:00
Earnings2019/10/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.